<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Older patients are notably absent from clinical trials </plain></SENT>
<SENT sid="1" pm="."><plain>Thus, observational studies are the primary avenue for understanding the role of comorbidity in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> care and survival </plain></SENT>
<SENT sid="2" pm="."><plain>We examined the impact of comorbidity on systemic treatment initiation and 3-year survival in a cohort of older <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHODS: Our cohort comprised 2753 Australian veterans aged â‰¥65 years with full health coverage and a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registry notification for colorectal (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), breast, prostate or <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small-cell lung cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>We established comorbidities based on drugs prescribed in the 6 months prior to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosis </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Patients with higher comorbidity burden were more likely to receive systemic treatment for <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> [adjusted odds ratio 1.21, 95% confidence interval (CI) 1.05-1.39] but less likely for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> (0.63, 95% CI 0.45-0.86) </plain></SENT>
<SENT sid="6" pm="."><plain>After adjusting for receipt of treatment, increased comorbidity resulted in shorter survival for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> [adjusted hazard ratio (aHR) 1.16, 95% CI 1.07-1.26] and <z:hpo ids='HP_0003002'>breast cancer</z:hpo> (aHR 1.23, 95% CI 1.02-1.48) </plain></SENT>
<SENT sid="7" pm="."><plain>However, we did not demonstrate significant improvements in 3-year survival for patients receiving systemic treatment </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Comorbidity influences systemic treatment uptake and adversely affects survival, with impact dependent upon comorbidity and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> type </plain></SENT>
<SENT sid="9" pm="."><plain>Clinical trials should be undertaken in older patients to better understand the risks and benefits of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatments </plain></SENT>
</text></document>